Patents by Inventor Catherine CARRIERE

Catherine CARRIERE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141037
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: March 8, 2023
    Publication date: May 2, 2024
    Inventors: Catherine CARRIERE, Michael Molloy, Jay Rothstein, Linda Snyder
  • Publication number: 20230310634
    Abstract: The invention provides anti-VISTA antibody drug conjugates which may be used for targeted delivery of anti-inflammatory agents such as steroids to immune cells, e.g., myeloid cells. The invention also provides methods of using anti-VISTA antibody drug conjugates in the treatment of inflammatory and/or autoimmune conditions and/or for alleviating the toxicity of anti-inflammatory agents such as steroids.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 5, 2023
    Inventors: Jay Rothstein, Kierstin Bell, Catherine Carriere, Michael Molloy, Anna Kuta, Nicholas Schwertner, Maria Day, Xin Huang, Dov Pechenick, Toni Kline, Shibhani Rajanna, Yalin Guo, Yingcai (Ian) Wang, Jieyu Zhou, Sergey Seregin, Erin Clark, Labros Memetis, Julio Medina, Sheng Sun, Alexander Koval, Sravan Thummanapelli, Dmitry Borkin, Rajeshkumar Maganlal Loriya
  • Patent number: 11603402
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 14, 2023
    Assignees: ImmuNext, Inc., JANSSEN PHARMACEUTICAL NV
    Inventors: Catherine Carriere, Michael Molloy, Jay Rothstein, Linda Snyder, Gordon Powers
  • Publication number: 20220259310
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: March 1, 2022
    Publication date: August 18, 2022
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Catherine CARRIERE, Randolph J. NOELLE, Sabrina DELONG, Isabelle LEMERCIER
  • Publication number: 20210317207
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: March 19, 2021
    Publication date: October 14, 2021
    Inventors: Randolph J. NOELLE, Sabrina DELONG, Michael MOLLOY, Catherine CARRIERE, Jay ROTHSTEIN, Isabelle LEMERCIER
  • Publication number: 20210017281
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: January 21, 2021
    Inventors: Michael MOLLOY, Jay ROTHSTEIN, Catherine CARRIERE, Randolph J. NOELLE, Sabrina DELONG, Isabelle LEMERCIER
  • Publication number: 20190263931
    Abstract: This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions in vitro and/or in vivo. The invention also relates to therapeutic and diagnostic uses of these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing optionally wherein these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins and compositions containing are used in therapeutic regimens that further include the administration of other therapeutic agents, e.g., mitochondrial inhibitors and/or biguanides or small molecule MCT1 inhibitors.
    Type: Application
    Filed: January 4, 2019
    Publication date: August 29, 2019
    Inventors: Jay L. Rothstein, Grace Ki Jeong Lee, Kimberly P. Shigenaka, Marcia Gordon, Kim Quon, Philipe Gobeil, Catherine Carriere, Sergey Seregin, Yong Wang, Raphael D. Levy, Jordon K. Wang
  • Publication number: 20170306019
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 26, 2017
    Inventors: Catherine CARRIERE, Michael MOLLOY, Jay ROTHSTEIN
  • Publication number: 20170306020
    Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 26, 2017
    Inventors: Randolph J. NOELLE, Sabrina DELONG, Michael MOLLOY, Catherine CARRIERE, Jay ROTHSTEIN, Isabelle LEMERCIER